

Synthesis of 2-substituted 2*H*-chromenes using potassium vinyltrifluoroborates

Fei Liu^a, Todd Evans^b, Bhaskar C. Das^{a,b,*}

^a Department of Nuclear Medicine Albert Einstein College of Medicine, Bronx, NY 10461, United States

^b Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY 10461, United States

Received 6 December 2007; revised 28 December 2007; accepted 3 January 2008

Available online 8 January 2008

Abstract

2*H*-Chromenes were synthesized from salicylaldehyde using potassium vinylic borates in the presence of secondary amines. We synthesized these 2*H*-chromene derivatives as a part of an ongoing project to develop inhibitors for TGF- β receptors. Potassium vinyl trifluoroborates react with salicylaldehydes at 80 °C in the presence of a secondary amine and produced 2-substituted 2*H*-chromene derivatives with a 70–90% yield.

© 2008 Elsevier Ltd. All rights reserved.

Keywords: Chromenes; Potassium organic trifluoroborate; TGF- β inhibitors; Signal transduction

We have a long-term goal to develop novel chemical screens capable of analyzing important biological systems by interfacing libraries of small molecules, in the context of developing zebrafish embryos. Toward this end, we were interested in developing potential new inhibitors of TGF- β signaling using 2-substituted 2*H*-chromene derivatives.


2*H*-Chromenes are an important class of oxygenated heterocyclic compounds.¹ Many biologically active natural products contain a chromene ring system.² In recent years, there has been increased interest in the synthesis of 2*H*-chromenes due to the number of compounds that possess this group, and that show a variety of activities including as antidepressant, antihypertensive, anti-tubulin, antiviral, antioxidative, activator of potassium channels and inhibition of phosphodiesterase IV or dihydrofolate reductase.³ Based on the importance of these compounds, a number of research groups have developed methodologies to synthesize these compounds. The approaches used include

intramolecular cyclization of Wittig intermediates,⁴ microwave-assisted reaction of salicylaldehyde with enamines,⁵ catalytic Petasis reaction of salicylaldehydes,⁶ ring-closing olefin metathesis,⁷ Baylis–Hillman reaction of 2-hydroxybenzaldehydes with methyl vinyl ketones,⁸ Claisen rearrangement of propargyl phenol ethers,⁹ Pd-catalyzed ring closure of 2-isoprenyl phenols,¹⁰ electrocyclic ring closure of vinylquinone derivatives,¹¹ and the Ylide annulation reaction.¹² Despite the availability of these existing methods for the synthesis of chromene derivatives, there remains a demand for general strategies that can more efficiently provide variously substituted chromene systems.

In the context of our goal to generate small molecule probes to study the biology of key signal transduction pathways, including transforming growth factor beta (TGF- β) pathways, we were interested in developing improved methods for the synthesis of a 2*H*-chromene library.

In this Letter, we report a practical and highly efficient procedure for preparing diverse chromene derivatives using potassium vinyltrifluoroborate as a substrate for the Petasis reaction in the presence of catalytic amounts of dibenzylamine as a secondary base at 80 °C in dimethyl

* Corresponding author. Tel.: +1 718 430 2422; fax: +1 718 430 8853.
E-mail address: bdas@aecom.yu.edu (B. C. Das).



Scheme 1.

formide. This procedure is complementary to that of Finn and Kabalka, which in both cases uses boronic acid. The utility of organoboronic acids in organic synthesis has flourished in recent years, particularly through developments in Miyaura–Suzuki coupling,¹³ allyl-boration,^{14,15} copper catalyzed arylboronic acid–hetero atom coupling¹⁶










and Petasis reaction.^{17,18} However, these organoboron derivatives have many limitations:¹⁹ (i) quantitative analysis and stoichiometric reactions using boronic acids are often difficult because of the rapid equilibrium between the boronic acids and the corresponding cyclic, trimeric anhydrides (boroxines), (ii) the diols utilized to generate

Table 1
Synthesis of 2-substituted 2*H*-chromenes from salicylaldehydes in the presence of 20% mol dibenzylamine in DMF at 80 °C

Entry	Aldehydes	Potassium vinylboronic	Product ^a	Yield ^b (%)
1				51
2				89
3				71
4				90
5				54
6				83
7				78

(continued on next page)

Table 1 (continued)

Entry	Aldehydes	Potassium vinylboronic	Product ^a	Yield ^b (%)
8				65
9				85
10				87

^a All products exhibited ¹H NMR and ¹³C NMR characteristics in accord with assigned structures and literature values (for known compounds) and high resolution mass spectrometry.

^b Isolated yields.

stable boronate esters such as catechol, pinacol, and diethanolamine add considerable expense to the overall process and they must be separated from the final product, further increasing the cost of synthesis.

(iii) Boronate esters, as Lewis acids and electrophiles, to elaborate the functionalization of multistep synthesis using nucleophiles, hamper the reaction process. To overcome all these difficulties using organoboron derivatives, the use of potassium organotrifluoroborates was developed. These reagents are easily prepared by the addition of inexpensive KHF₂ to various organoboron intermediates,^{20a–c} from organostannate^{20f} and by C–H activation method.^{20g} For our reaction, we purchased all alkenyl trifluoroborates from Aldrich chemicals. All these salts have been described as being very stable at elevated temperature. Potassium organotrifluoroborates are more stable and easier to handle than the corresponding organoboronic acids, and they are more reactive due to the higher nucleophilicity of the organic group on the boron atom. Due to these distinctive features (greater nucleophilicity, ready accessibility, and remarkable stability in air), organotrifluoroborate have been used for many organic reactions, as reported by Kabalka, Molander, Genet and others.²¹

In this Letter, we report a practical and highly efficient procedure for preparing diverse chromene derivatives, and demonstrate the practical utility of potassium organotrifluoroborate in chromene synthesis.

As shown in Scheme 1, salicylaldehyde (1 mmol), vinyl boronic acid (1 mmol) and dibenzylamine (20 mol %) was added to DMF and the solution was stirred at 80 °C for 3 h. The reaction was monitored through thin layer chromatography (solvent system). Unexpectedly we identified a novel spot, and after workup NMR analysis determined it that comprised 2-phenyl chromenes.²² To generalize this

methodology, we worked with a variety of substituted salicylaldehydes and boronic acids, as shown in Table 1. We purified all products by column chromatography and the reported yields are the isolated yields. The purity of the products was subsequently established by thin layer chromatography, ¹H NMR, ¹³C NMR and by high resolution mass spectrometry. For all new products, experimental procedures and analytical data are provided in Ref. 22, and for all known compounds we compared the analytical data with our compounds (which were identical).

A somewhat higher yield is obtained in the case of electron withdrawing groups in the *para* position of salicylaldehydes, as compared to unsubstituted functional groups. When we changed from potassium *trans*-styryltrifluoroborate to potassium vinyltrifluoroborate the yields decreased, except in the case of potassium *trans*-1-decyltrifluoroborate, where the yield remained similar.

In summary, we report a practical synthesis of chromene derivatives using potassium organotrifluoroborate. Experiments are currently underway to test the biological activity of these 2*H* derivatives and to determine their utility as inhibitors of TGF-β receptors.

Acknowledgments

The author BCD acknowledges Professor M. Donald Blaufox for his financial support and encouragement and AECOM for startup funding.

References and notes

- (a) Hepworth, J. D. *Pyrans and Fused Pyrans: Synthesis and Applications*. In *Comprehensive Heterocyclic Chemistry*; Katritzky, A. R., Rees, C. W., Eds.; Pergamon: Oxford, 1984; Vol. 3, p 737; (b)

- Milcent, R.; Chau, F. *Chimie Organique He'terocyclique*; EDP Sciences: Les Ulis, France, 2003; p 434.
- (a) Nicolaou, K. C.; Pfeifferkorn, J. A.; Cao, G.-Q. *Angew. Chem., Int. Ed.* **2000**, *39*, 734; (b) Nicolaou, K. C.; Cao, G.-Q.; Pfeifferkorn, J. A. *Angew. Chem., Int. Ed.* **2000**, *39*, 739; (c) Trost, B. M.; Trost, F. D. *J. Am. Chem. Soc.* **1998**, *120*, 9074; (d) Varma, R. S.; Dahiya, R. *J. Org. Chem.* **1998**, *63*, 8038; (e) Miao, H.; Yang, Z. *Org. Lett.* **2000**, *2*, 1765; (f) Maggiani, A.; Tubul, A.; Brun, P. *Helv. Chem. Acta* **2000**, *83*, 650.
 - (a) Evans, J. M.; Fake, C. S.; Hamilton, T. C.; Poyser, R. H.; Watts, E. A. *J. Med. Chem.* **1983**, *26*, 1582; (b) Ashwood, V. A.; Buckingham, R. E.; Cassidy, F.; Evans, J. M.; Faruk, E. A.; Hamilton, T. C.; Nash, D. J.; Stemp, G.; Willcocks, K. *J. Med. Chem.* **1986**, *29*, 2194; (c) Bergmann, R.; Gericke, R. *J. Med. Chem.* **1990**, *33*, 492; (d) Gericke, R.; Harting, J.; Lues, I.; Schittenhelm, C. *J. Med. Chem.* **1991**, *34*, 3074; (e) Cassidy, F.; Evans, J. M.; Hadley, M. S.; Haladj, A. H.; Leach, P. E.; Stemp, G. *J. Med. Chem.* **1992**, *35*, 1623; (f) D. Pinney G. Kevin.; Arthasary, P.; Shirali, A.; Edvardsen, K.; Chaplin, D.J. U.S. Patent. US2005/024590A1; (g) Wipf, P.; Weiner, W. S. *J. Org. Chem.* **1999**, *65*, 5321; (h) Jankun, J.; Selman, S. H.; Swiercz, R.; Skrzypczak-Jankun, E. *Nature* **1997**, *387*, 561; (i) Van Lommen, G.; De Bruyn, M.; Schoven, M. *J. Pharm. Belg.* **1990**, *45*, 355–360; (j) Covington, A. D. *Chem. Soc. Rev.* **1997**, 111–126.
 - Hanamoto, T.; Shindo, K.; Matsuoka, M.; Kiguchi, Y.; Kondo, M. *J. Chem. Soc., Perkin Trans. 1* **2000**, 3082.
 - Varma, R. S.; Dahiya, R. *J. Org. Chem.* **1998**, *63*, 8038.
 - (a) Wang, Q.; Finn, M. G. *Org. Lett.* **2000**, *2*, 4063–4065; (b) Kabalka, G. W.; Venkataiah, B.; Das, Bhaskar. C. *Synlett* **2004**, 2194–2196.
 - Chang, S.; Grubbs, R. H. *J. Org. Chem.* **1998**, *63*, 864.
 - Kaye, P. T.; Nocanda, X. W. *J. Chem. Soc., Perkin Trans. 1* **2000**, 1331.
 - Hlubec, J.; Ritchie, E.; Taylor, W. C. *Tetrahedron Lett.* **1969**, 1369.
 - Iyer, M.; Trivedi, G. R. *Synth. Commun.* **1990**, *20*, 1347.
 - Parker, K. A.; Mindt, T. L. *Org. Lett.* **2001**, *3*(24), 3875.
 - Ye, L. Wu.; Sun, Xiu-L.; Zhu, Chun-Y.; Tang, Y. *Org. Lett.* **2006**, *8*, 3853–3856.
 - Miyaura, N.; Suzuki, A. *Chem. Rev.* **1995**, *95*, 2457–2483.
 - Roush, W. R.; Adam, M. A.; Walts, A. E.; Harris, D. J. *J. Am. Chem. Soc.* **1986**, *108*, 3422–3434.
 - Flamme, E. M.; Roush, W. R. *J. Am. Chem. Soc.* **2002**, *124*, 13644–13645.
 - Ley, S. V.; Thomas, A. W. *Angew. Chem., Int. Ed.* **2003**, *42*, 5400–5449.
 - Petasis, N. A.; Zavalov, I. A. *J. Am. Chem. Soc.* **1997**, *119*, 445–446.
 - Petasis, N. A.; Yudin, A. K.; Zavalov, I. A.; Prakash, G. K. S.; Olah, G. A. *Synlett* **1997**, 606–608.
 - Molander, G. A.; Ham, J. *Org. Lett.* **2006**, *8*, 2031–2034.
 - For the synthesis of organotrifluoroborates, see: (a) Vedejs, E.; Chapman, R. W.; Fields, S. C.; Lin, S.; Schrimpf, M. R. *J. Org. Chem.* **1995**, *60*, 3020; (b) Vedejs, E.; Fields, S. C.; Hayashi, R.; Hitchcock, S. R.; Powell, D. R.; Schrimpf, M. R. *J. Am. Chem. Soc.* **1999**, *121*, 2460; (c) Molander, G. A.; Figueroa, R. *Aldrichim. Acta* **2005**, *38*, 49; (d) Darses, S.; Genet, J.-P. *Eur. J. Org. Chem.* **2003**, 4313; (e) Molander, G. A.; Ellis, N. *Acc. Chem. Res.* **2007**, *40*, 275–286; (f) Chambers, R. D.; Clark, H. C.; Willis, C. J. *J. Am. Chem. Soc.* **1960**, *82*, 5298–5301; (g) Takahashi, M.; Bae, C.; Hartwig, J. F. *J. Am. Chem. Soc.* **2004**, *126*, 15334.
 - Use of BF₃K in organic synthesis. (a) Kabalka, G. W.; Venkataiah, B.; Dong, G. *Org. Lett.* **2003**, 3803–3805; (b) Kabalka, G. W.; Reddy, M. *Organometallics* **2004**, *23*, 4519–4521; (c) Kabalka, G. W.; Venkataiah, B.; Dong, G. *Tetrahedron Lett.* **2004**, 729–731; (d) Kabalka, G. W.; Dong, G.; Venkataiah, B. *Tetrahedron Lett.* **2005**, *46*, 763–765; (e) Molander, G. A.; Katona, B. W.; Machrouhi, F. J. *Org. Chem.* **2002**, *67*, 8416; (f) Darses, S.; Michaud, G.; Genet, J.-P. *Eur. J. Org. Chem.* **1999**, 1875; (g) Vedejs, E.; Chapman, R. W.; Fields, S. C.; Lin, S.; Schrimpf, M. R. *J. Org. Chem.* **1995**, *60*, 3020; (h) Darses, S.; Michaud, G.; Genet, J.-P. *Tetrahedron Lett.* **1998**, *39*, 5045; (i) Molander, G. A.; Biolatto, B. *Org. Lett.* **2002**, *4*, 1867; (j) Molander, G. A.; Petrillo, D. E. *J. Am. Chem. Soc.* **2006**, *128*, 9634–9635; (k) Molander, G. A.; Ribagorda, M. *J. Am. Chem. Soc.* **2003**, *125*, 11148–11149; (l) Molander, G. A.; Figueroa, R. *Org. Lett.* **2006**, *8*, 75–78; (m) Stefani, H. A.; Cella, R.; Dörr, F. A.; Pereira, C. M. P.; Zeni, G.; Gomes, M., Jr. *Tetrahedron Lett.* **2005**, *46*, 563–567; (n) Fang, G.-H.; Yan, Z.-J.; Deng, M.-Z. *Org. Lett.* **2004**, *6*, 357–360.
 - Experimental details: Synthesis of compound 11:** A solution of 2,3-dihydroxybenzaldehyde (276.2 mg, 2 mmol), potassium *trans*-styryl-trifluoroborate (420 mg, 2 mmol), was added with dibenzylamine (82 mg, 20 mol %) in anhydrous DMF (10 mL). The reaction mixture was heated at 80 °C overnight. The reaction mixture was quenched with aqueous saturated NH₄Cl (8 mL), extracted with CH₂Cl₂ (10 mL × 3), and combined organic layers were washed with water (10 mL × 3). The water layer was extracted with CH₂Cl₂ (5 mL × 2). The combined organic layers were dried with Na₂SO₄, and evaporated. The residue was purified by flash column chromatography using hexane–ethyl acetate (98:2) as the eluent to give a yellow solid, 242.2 mg (54.0%). ¹H NMR (300 MHz, CDCl₃): δ 7.50–7.39 (m, 5H), 6.87–6.82 (m, 2H), 6.67 (dd, *J* = 6.9, 2.4 Hz, 1H), 6.60 (dd, *J* = 9.9, 2.1 Hz, 1H), 5.98 (t, *J* = 3 Hz, 1H), 5.85 (dd, *J* = 9.9, 3.3 Hz, 1H), 5.44 (s, 1H). ¹³C NMR CD₃OD: δ 145.04, 141.31, 140.65, 128.49, 126.94, 125.20, 123.97, 122.63, 121.14, 117.80, 116.47, 77.10. ESI MS: calcd for C₁₅H₁₂O₂ ([M+H]⁺) 225.088; found: 225.12.
Compound 19: A solution of 2-hydroxy-5-nitrobenzaldehyde (272.92 mg, 1.6 mmol), potassium *trans*-1-decenyltrifluoroborate (402 mg, 1.6 mmol), was added with dibenzylamine (82 mg, 20 mol %) in anhydrous DMF (8 mL). The reaction mixture was heated at 80 °C overnight. The reaction mixture was quenched with aqueous saturated NH₄Cl (8 mL), extracted with CH₂Cl₂ (10 mL × 3), and the combined organic layers were washed with water (10 mL × 3). The water layer was extracted with CH₂Cl₂ (5 mL × 2). The combined organic layers were dried with Na₂SO₄, and evaporated. The residue was purified by flash column chromatography using hexane–ethyl acetate/98:2 as the eluent to give a yellow solid, 402.15 mg (85.1%). ¹H NMR (300 MHz, CDCl₃): δ 7.99 (dd, *J* = 8.85, 2.4 Hz, 1H), 7.83 (d, *J* = 2.7 Hz, 1H), 6.78 (d, *J* = 8.7 Hz, 1H), 6.40 (dd, *J* = 10.8, 1.2 Hz, 1H), 5.79 (dd, *J* = 12, 1.5 Hz, 1H), 5.04–5.01 (m, 1H), 1.82–1.70 (m, 2H), 1.52–1.31 (m, 2H), 1.26 (br s, 10H), 0.875 (t, *J* = 6.3 Hz, 3H). ¹³C NMR CD₃COCD₃: δ 159.56, 141.87, 128.03, 125.64, 122.65, 121.83, 116.48, 77.48, 36.34, 32.23, 24.94, 23.04, 14.84. ESI MS calcd for C₁₇H₂₃NO₃ ([M⁺–H]⁺): 288.1521; found: 288.120.
Compound 20: A solution of 3,5-dichlorosalicylaldehyde (382 mg, 2 mmol), potassium *trans*-1-decenyltrifluoroborate (492 mg, 2 mmol), was added with dibenzylamine (82 mg, 20 mol %) in anhydrous DMF (10 mL). The reaction mixture was heated at 80 °C overnight. The reaction mixture was quenched with aqueous saturated NH₄Cl (8 mL), extracted with CH₂Cl₂ (15 mL × 3), and the combined organic layers were washed with water (10 mL × 3). The water layer was extracted with CH₂Cl₂ (10 mL × 2). The combined organic layers were dried with Na₂SO₄, and evaporated. The residue was purified by flash column chromatography using hexane as the eluent to give a yellow solid, 545.00 mg (87.00%). ¹H NMR (300 MHz, CDCl₃): δ 7.16 (d, *J* = 2.1 Hz, 1H), 6.85 (d, *J* = 2.4 Hz, 1H), 6.33 (dd, *J* = 9.9, 1.5 Hz, 1H), 5.82 (dd, *J* = 9.8, 3.6 Hz, 1H), 4.95 (m, 1H), 1.83–1.46 (m, 4H), 1.30 (br s, 10H), 0.93 (t, *J* = 6.3 Hz, 3H). ¹³C NMR CDCl₃: δ 148.22, 129.25, 128.41, 125.73, 124.89, 124.52, 122.80, 122.12, 76.67, 35.71, 32.27, 29.75, 25.24, 23.09, 14.52. ESI MS calcd for C₁₇H₂₂Cl₂O ([M⁺–H]⁺): 311.097; found: 311.0903.